Antibiotic Hypersensitivity in Cystic Fibrosis - Low Frequency of Anaphylaxis over 16 000 Courses

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2022 Jun 7

PMID 35671007

Authors

Aleksandra Kowalik

Isabelle de Monestrol

Kimmo Sorjonen

Knut Brockow

Theo Gulen

Affiliations

Soon will be listed here.

Abstract

Aims: Drug hypersensitivity reactions (DHR) to antibiotics are common and a substantial issue in managing patients with cystic fibrosis (CF). This study aimed to assess the prevalence and clinical features as well as risk factors of DHR to antibiotics in CF.

Method: A 20-year retrospective study was conducted among 226 CF patients (100 children and 126 adults) attending our centre. The Swedish Registry for Cystic Fibrosis and electronic medical records enabled us to ascertain the number and routes of antibiotic courses. All suspected DHR were evaluated.

Results: The patients had a total of 16 910 antibiotic courses, of which 6832 (40%) were intravenously administered. Of 226 enrolled CF patients, 70 (31%) developed overall 131 DHR to antibiotics. The prevalence of DHR increased with advancing age (P < .001). Beta-lactams elicited 71% of all DHR and piperacillin was the most common single culprit (30% of intravenous and 24% of all DHR). Reactions were mild to moderate and mostly limited to skin; no severe cutaneous adverse reactions were observed. Additionally, anaphylaxis was rare, constituting 2.3% (3/131) of all DHR. Patients with DHR were exposed to significantly more courses of antibiotics than those without DHR (median 124 vs. 46, retrospectively, P < .001).

Conclusions: DHR to antibiotics, particularly to beta-lactams, are increased in CF patients, and associated with a higher number of cumulative exposures because of recurrent infections. However, severe cutaneous or systemic DHR, such as anaphylaxis, appear to be rare.

Citing Articles

Risk factors for drug hypersensitivity reactions in children.

Mori F, Saretta F, Riscassi S, Caimmi S, Bottau P, Liotti L Ital J Pediatr. 2024; 50(1):127.

PMID: 39010141 PMC: 11247891. DOI: 10.1186/s13052-024-01694-x.

Protein Haptenation and Its Role in Allergy.

Aleksic M, Meng X Chem Res Toxicol. 2024; 37(6):850-872.

PMID: 38834188 PMC: 11187640. DOI: 10.1021/acs.chemrestox.4c00062.

Diagnostic Evaluation of Hypersensitivity Reactions to Antibiotics in a Large Cohort of Mastocytosis Patients.

Jarkvist J, Gulen T Diagnostics (Basel). 2023; 13(13).

PMID: 37443635 PMC: 10340660. DOI: 10.3390/diagnostics13132241.

Antibiotic hypersensitivity in cystic fibrosis - Low frequency of anaphylaxis over 16 000 courses.

Kowalik A, de Monestrol I, Sorjonen K, Brockow K, Gulen T Br J Clin Pharmacol. 2022; 88(11):4845-4853.

PMID: 35671007 PMC: 9796175. DOI: 10.1111/bcp.15434.

References

Stevenson D, Kowalski M . An epidemic of over diagnosing drug allergies. Allergy Asthma Proc. 2014; 35(2):92-4. DOI: 10.2500/aap.2014.35.1015. View

Matar R, Le Bourgeois M, Scheinmann P, De Blic J, Ponvert C . Beta-lactam hypersensitivity in children with cystic fibrosis: a study in a specialized pediatric center for cystic fibrosis and drug allergy. Pediatr Allergy Immunol. 2013; 25(1):88-93. DOI: 10.1111/pai.12154. View

Muraro A, Worm M, Alviani C, Cardona V, DunnGalvin A, Garvey L . EAACI guidelines: Anaphylaxis (2021 update). Allergy. 2021; 77(2):357-377. DOI: 10.1111/all.15032. View

Scherer K, Brockow K, Aberer W, Gooi J, Demoly P, Romano A . Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the Drug Allergy Interest Group. Allergy. 2013; 68(7):844-52. DOI: 10.1111/all.12161. View

Braun C, Reix P, Durieu I, Nove-Josserand R, Durupt S, Ohlmann C . The diagnosis of hypersensitivity to antibiotics is rarely confirmed by allergy work-up in cystic fibrosis patients. Pediatr Allergy Immunol. 2019; 31(4):396-404. DOI: 10.1111/pai.13206. View

Adkinson Jr N . Risk factors for drug allergy. J Allergy Clin Immunol. 1984; 74(4 Pt 2):567-72. DOI: 10.1016/0091-6749(84)90108-8. View

Shehab N, Patel P, Srinivasan A, Budnitz D . Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis. 2008; 47(6):735-43. DOI: 10.1086/591126. View

Lang D, Lang E, Portnoy J, Riblet N, Bobrownicki A, Bontrager T . Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020; 145(4):1082-1123. DOI: 10.1016/j.jaci.2020.01.017. View

Brockow K, Ardern-Jones M, Mockenhaupt M, Aberer W, Barbaud A, Caubet J . EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy. 2018; 74(1):14-27. DOI: 10.1111/all.13562. View

10.

Brockow K . Triage Strategies for Clarifying Reported Betalactam Allergy. J Allergy Clin Immunol Pract. 2019; 7(3):1066-1067. DOI: 10.1016/j.jaip.2018.08.009. View

11.

Patel R, Gallagher J . Drug fever. Pharmacotherapy. 2009; 30(1):57-69. DOI: 10.1592/phco.30.1.57. View

12.

LEVINE B . Immunologic mechanisms of penicillin allergy. A haptenic model system for the study of allergic diseases of man. N Engl J Med. 1966; 275(20):1115-25. DOI: 10.1056/NEJM196611172752009. View

13.

Roehmel J, Schwarz C, Mehl A, Stock P, Staab D . Hypersensitivity to antibiotics in patients with cystic fibrosis. J Cyst Fibros. 2013; 13(2):205-11. DOI: 10.1016/j.jcf.2013.10.002. View

14.

Romano A, Atanaskovic-Markovic M, Barbaud A, Bircher A, Brockow K, Caubet J . Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper. Allergy. 2019; 75(6):1300-1315. DOI: 10.1111/all.14122. View

15.

Macy E, Contreras R . Adverse reactions associated with oral and parenteral use of cephalosporins: A retrospective population-based analysis. J Allergy Clin Immunol. 2014; 135(3):745-52.e5. DOI: 10.1016/j.jaci.2014.07.062. View

16.

Macy E, Poon K-Y T . Self-reported antibiotic allergy incidence and prevalence: age and sex effects. Am J Med. 2009; 122(8):778.e1-7. DOI: 10.1016/j.amjmed.2009.01.034. View

17.

Pleasants R, Walker T, Samuelson W . Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis. Chest. 1994; 106(4):1124-8. DOI: 10.1378/chest.106.4.1124. View

18.

Wright M, Bush A, Carr S . Hypersensitivity reactions to intravenous antibiotics in cystic fibrosis. Paediatr Respir Rev. 2018; 27:9-12. DOI: 10.1016/j.prrv.2018.01.003. View

19.

Burrows J, Nissen L, Kirkpatrick C, Bell S . Beta-lactam allergy in adults with cystic fibrosis. J Cyst Fibros. 2006; 6(4):297-303. DOI: 10.1016/j.jcf.2006.11.001. View

20.

Kowalik A, de Monestrol I, Sorjonen K, Brockow K, Gulen T . Antibiotic hypersensitivity in cystic fibrosis - Low frequency of anaphylaxis over 16 000 courses. Br J Clin Pharmacol. 2022; 88(11):4845-4853. PMC: 9796175. DOI: 10.1111/bcp.15434. View